Why Is TScan Therapeutics Stock Gaining Today?
Why Is TScan Therapeutics Stock Gaining Today?
According to Benzinga Pro, TCRX stock has lost over 51% in the past year. TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday.
TScan Therapeutics, Inc. (納斯達克:TCRX) 的股票在週四的盤前交易中上漲。
The firm announced a significant financing deal, entering into a securities purchase agreement with Lynx1 Capital Management LP and an investment fund advised by Lynx1.
該公司宣佈了一項重要的融資交易，與Lynx1資本管理公司和一家由Lynx1顧問的投資基金簽署了證券購買協議。
Under the agreement, TScan will sell approximately $30 million in pre-funded warrants, which are exercisable for up to 7.50 million shares of its voting common stock.
根據協議，TScan將出售約3000萬美元的預付Warrants，這些Warrants可行使購買高達750萬股其投票普通股。
According to Benzinga Pro, TCRX stock has lost over 51% in the past year.
根據Benzinga Pro，TCRX股票在過去一年中已損失超過51%。
Each warrant will be priced at $4.00, with an exercise price of $0.0001 per share.
每份Warrant的價格爲4.00美元，行使價格爲每股0.0001美元。
This deal represents a 37% premium over TScan's last closing price and a 34% premium compared to its 10-day volume-weighted average closing price. The financing is expected to close by December 27, 2024, pending customary closing conditions.
這項交易相較於TScan上次收盤價有37%的溢價，相較於其10天成交量加權平均收盤價有34%的溢價。融資預計將在2024年12月27日前完成，待完成慣例的交易條件。
Also Read: US Stocks Likely To Open In Red After Christmas Break But Analysts Still Expect A Santa Rally Into The New Year
另請閱讀：美國股票在聖誕假期後可能以紅色開盤，但分析師仍然期待新年期間的聖誕反彈。
Gavin MacBeath, Ph.D., CEO of TScan Therapeutics, expressed appreciation for Lynx1's continued support, highlighting the investment as a testament to their commitment to TScan's mission of delivering life-changing TCR-T cell therapies for cancer patients.
TScan Therapeutics的首席執行官Gavin MacBeath博士對Lynx1的持續支持表示感謝，強調此次投資證明了他們對TScan使命的承諾，即爲癌症患者提供改變生活的TCR-t細胞療法。
Jason A. Amello, CFO of TScan, added that the additional $30 million in gross proceeds will extend the company's cash runway, now expected to fund operations into the first quarter of 2027, up from the previous expectation of the fourth quarter of 2026.
TScan的財務長Jason A. Amello補充說，額外的3000萬美元收益將延長公司的現金運營期，現在預計將資金支持到2027年第一季度，高於之前預計的2026年第四季度。
This funding comes after TScan filed a registration statement with the SEC in November 2022, which was declared effective in May 2023.
此次融資是在TScan於2022年11月向美國證券交易委員會提交註冊聲明後進行的，該聲明在2023年5月生效。
Price Action: TCRX shares are trading higher by 16.8% to $3.40 premarket at last check Thursday.
價格動態：根據週四最後的檢查，TCRX的股價在盤前交易中上漲了16.8%，達到了3.40美元。
Photo via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
